Anirvan Ghosh - 28 Mar 2025 Form 4 Insider Report for Unity Biotechnology, Inc. (UBX)

Signature
/s/ Alexander Nguyen, Attorney-in-Fact for Anirvan Ghosh
Issuer symbol
UBX
Transactions as of
28 Mar 2025
Net transactions value
$0
Form type
4
Filing time
31 Mar 2025, 16:15:03 UTC
Previous filing
05 Feb 2025
Next filing
03 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UBX Common Stock, $0.0001 par value Award $0 +175,000 +233% $0.000000 250,251 28 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UBX Stock Option (Right to Buy) Award $0 +286,000 $0.000000 286,000 28 Mar 2025 Common Stock 286,000 $1.67 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 30, 2024, the Board of Directors granted the Reporting Person 175,000 Restricted Stock Units ("RSUs") that vest in full upon the satisfaction of certain performance criteria, which were met on March 28, 2025.
F2 Includes RSUs that vest over time measured from the grant date.
F3 On January 30, 2024, the Board of Directors granted the Reporting Person an option to purchase 286,000 shares of common stock. The underlying shares vest and become exercisable pursuant to the following schedule: one half of the shares subject to the option vest upon the satisfaction of certain performance criteria, which were met on March 28, 2025, and the remaining shares subject to the option vest in 12 successive, equal monthly installments thereafter until fully vested, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.